RT Journal Article
SR Electronic
T1 Gestational choriocarcinoma
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1504
OP 1514
DO 10.1136/ijgc-2023-004704
VO 33
IS 10
A1 Bogani, Giorgio
A1 Ray-Coquard, Isabelle
A1 Mutch, David
A1 Vergote, Ignace
A1 Ramirez, Pedro T
A1 Prat, Jaime
A1 Concin, Nicole
A1 Ngoi, Natalie Yan Li
A1 Coleman, Robert L
A1 Enomoto, Takayuki
A1 Takehara, Kazuhiro
A1 Denys, Hannelore
A1 Lorusso, Domenica
A1 Takano, Masashi
A1 Sagae, Satoru
A1 Wimberger, Pauline
A1 Segev, Yakir
A1 Kim, Se Ik
A1 Kim, Jae-Weon
A1 Herrera, Fernanda
A1 Mariani, Andrea
A1 Brooks, Rebecca A
A1 Tan, David
A1 Paolini, Biagio
A1 Chiappa, Valentina
A1 Longo, Mariangela
A1 Raspagliesi, Francesco
A1 Benedetti Panici, Pierluigi
A1 Di Donato, Violante
A1 Caruso, Giuseppe
A1 Colombo, Nicoletta
A1 Pignata, Sandro
A1 Zannoni, Gianfranco
A1 Scambia, Giovanni
A1 Monk, Bradley J
YR 2023
UL http://ijgc.bmj.com/content/33/10/1504.abstract
AB Gestational choriocarcinoma accounts for 5% of gestational trophoblastic neoplasms. Approximately 50%, 25%, and 25% of gestational choriocarcinoma occur after molar pregnancies, term pregnancies, and other gestational events, respectively. The FIGO scoring system categorizes patients into low (score 0 to 6) and high risk (score 7 or more) choriocarcinoma. Single-agent and multi-agent chemotherapy are used in low- and high-risk patients, respectively. Chemotherapy for localized disease has a goal of eradication of disease without surgery and is associated with favorable prognosis and fertility preservation. Most patients with gestational choriocarcinoma are cured with chemotherapy; however, some (<5.0%) will die as a result of multi-drug resistance, underscoring the need for novel approaches in this group of patients. Although there are limited data due to its rarity, the treatment response with immunotherapy is high, ranging between 50–70%. Novel combinations of immune checkpoint inhibitors with targeted therapies (including VEGFR-2 inhibitors) are under evaluation. PD-L1 inhibitors are considered a potential important opportunity for chemo-resistant patients, and to replace or de-escalate chemotherapy to avoid or minimize chemotherapy toxicity. In this review, the Rare Tumor Working Group and the European Organization for Research and Treatment of Cancer evaluated the current landscape and further perspective in the management of patients diagnosed with gestational choriocarcinoma.